Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
Molecular mechanisms of cell cycle block by methionine restriction in human prostate cancer cells
14:10 diet 14 hours of fasting and 10 hours of food intake, usually between 10:00 AM and 8:00 PM
Retatrutide Clinical Research Findings The clinical development program for retatrutide has produced compelling data across multiple research endpoints: Weight Loss Efficacy: Phase 2 trials showed dose-dependent weight reduction ranging from 8.7% at the lowest dose to 24.2% at the highest dose over 48 weeks Metabolic Improvements: Participants demonstrated improvements in glycemic control, lipid profiles, and blood pressure measurements Safety Profile: Gastrointestinal effects (nausea, vomiting, diarrhea) were the most common adverse events, occurring in 60-80% of participants but generally rated as mild to moderate in severity Sustained Effects: Weight loss continued throughout the trial period without evidence of plateau, suggesting ongoing metabolic benefits These findings have positioned retatrutide as a leading candidate for advanced metabolic research
Alongside BPC-157 treatment, we may recommend additional therapies, lifestyle modifications, and preventive care strategies to enhance your overall health and well-being
US$ 23.95
US$ 28.66
US$ 26.51
US$ 20.40
US$ 24.62